Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2019, Article ID 7901062, 16 pages
https://doi.org/10.1155/2019/7901062
Research Article

Association between Adipose Tissue Interleukin-33 and Immunometabolic Markers in Individuals with Varying Degrees of Glycemia

1Research Division, Dasman Diabetes Institute, Dasman 15462, Kuwait
2Medical Division, Dasman Diabetes Institute, Dasman 15462, Kuwait
3Department of Medicine, Faculty of Medicine, Kuwait

Correspondence should be addressed to Amal Hasan; gro.etutitsninamsad@nasah.lama

Received 9 October 2018; Accepted 17 December 2018; Published 3 April 2019

Academic Editor: Mariann Harangi

Copyright © 2019 Amal Hasan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. E. Kahn, R. L. Hull, and K. M. Utzschneider, “Mechanisms linking obesity to insulin resistance and type 2 diabetes,” Nature, vol. 444, no. 7121, pp. 840–846, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. M. F. Gregor and G. S. Hotamisligil, “Inflammatory mechanisms in obesity,” Annual Review of Immunology, vol. 29, no. 1, pp. 415–445, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Barbarroja, R. López-Pedrera, M. D. Mayas et al., “The obese healthy paradox: is inflammation the answer?” The Biochemical Journal, vol. 430, no. 1, pp. 141–149, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Gesta, Y. H. Tseng, and C. R. Kahn, “Developmental origin of fat: tracking obesity to its source,” Cell, vol. 131, no. 2, pp. 242–256, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. E. D. Rosen and B. M. Spiegelman, “What we talk about when we talk about fat,” Cell, vol. 156, no. 1-2, pp. 20–44, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Frontini and S. Cinti, “Distribution and development of brown adipocytes in the murine and human adipose organ,” Cell Metabolism, vol. 11, no. 4, pp. 253–256, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Bartelt and J. Heeren, “Adipose tissue browning and metabolic health,” Nature Reviews Endocrinology, vol. 10, no. 1, pp. 24–36, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Harms and P. Seale, “Brown and beige fat: development, function and therapeutic potential,” Nature Medicine, vol. 19, no. 10, pp. 1252–1263, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Bartelt, O. T. Bruns, R. Reimer et al., “Brown adipose tissue activity controls triglyceride clearance,” Nature Medicine, vol. 17, no. 2, pp. 200–205, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Chondronikola, E. Volpi, E. Borsheim et al., “Brown adipose tissue improves whole-body glucose homeostasis and insulin sensitivity in humans,” Diabetes, vol. 63, no. 12, pp. 4089–4099, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. O. Osborn and J. M. Olefsky, “The cellular and signaling networks linking the immune system and metabolism in disease,” Nature Medicine, vol. 18, no. 3, pp. 363–374, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Mathis, “Immunological goings-on in visceral adipose tissue,” Cell Metabolism, vol. 17, no. 6, pp. 851–859, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. J. I. Odegaard and A. Chawla, “The immune system as a sensor of the metabolic state,” Immunity, vol. 38, no. 4, pp. 644–654, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. J. I. Odegaard and A. Chawla, “Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis,” Science, vol. 339, no. 6116, pp. 172–177, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. J. R. Brestoff and D. Artis, “Immune regulation of metabolic homeostasis in health and disease,” Cell, vol. 161, no. 1, pp. 146–160, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. V. Carriere, L. Roussel, N. Ortega et al., “IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 1, pp. 282–287, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Moussion, N. Ortega, and J. P. Girard, “The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’?” PLoS One, vol. 3, no. 10, article e3331, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. A. M. Miller, D. L. Asquith, A. J. Hueber et al., “Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice,” Circulation Research, vol. 107, no. 5, pp. 650–658, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Kolodin, N. van Panhuys, C. Li et al., “Antigen- and cytokine-driven accumulation of regulatory T cells in visceral adipose tissue of lean mice,” Cell Metabolism, vol. 21, no. 4, pp. 543–557, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. A. B. Molofsky, F. van Gool, H. E. Liang et al., “Interleukin-33 and interferon-γ counter-regulate group 2 innate lymphoid cell activation during immune perturbation,” Immunity, vol. 43, no. 1, pp. 161–174, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Pichery, E. Mirey, P. Mercier et al., “Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain,” The Journal of Immunology, vol. 188, no. 7, pp. 3488–3495, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. I. S. Wood, B. Wang, and P. Trayhurn, “IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes,” Biochemical and Biophysical Research Communications, vol. 384, no. 1, pp. 105–109, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Zeyda, B. Wernly, S. Demyanets et al., “Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue,” International Journal of Obesity, vol. 37, no. 5, pp. 658–665, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. W. P. Arend, G. Palmer, and C. Gabay, “IL-1, IL-18, and IL-33 families of cytokines,” Immunological Reviews, vol. 223, no. 1, pp. 20–38, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Löhning, J. L. Grogan, A. J. Coyle et al., “T1/ST2 expression is enhanced on CD4+ T cells from schistosome egg-induced granulomas: analysis of Th cell cytokine coexpression ex vivo,” The Journal of Immunology, vol. 162, no. 7, pp. 3882–3889, 1999. View at Google Scholar
  26. H. Hayakawa, M. Hayakawa, A. Kume, and S. I. Tominaga, “Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation,” The Journal of Biological Chemistry, vol. 282, no. 36, pp. 26369–26380, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. V. Trajkovic, M. J. Sweet, and D. Xu, “T1/ST2--an IL-1 receptor-like modulator of immune responses,” Cytokine & Growth Factor Reviews, vol. 15, no. 2-3, pp. 87–95, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Lohning, A. Stroehmann, A. J. Coyle et al., “T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 12, pp. 6930–6935, 1998. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Zhang, A. M. Ramadan, B. Griesenauer et al., “ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease,” Science Translational Medicine, vol. 7, no. 308, article 308ra160, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Xu, W. L. Chan, B. P. Leung et al., “Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells,” The Journal of Experimental Medicine, vol. 187, no. 5, pp. 787–794, 1998. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Schiering, T. Krausgruber, A. Chomka et al., “The alarmin IL-33 promotes regulatory T-cell function in the intestine,” Nature, vol. 513, no. 7519, pp. 564–568, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. B. M. Matta, D. K. Reichenbach, X. Zhang et al., “Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD,” Blood, vol. 128, no. 3, pp. 427–439, 2016. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Blom, B. C. Poulsen, B. M. Jensen, A. Hansen, and L. K. Poulsen, “IL-33 induces IL-9 production in human CD4+ T cells and basophils,” PLoS One, vol. 6, no. 7, article e21695, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Gerlach, Y. Y. Hwang, A. Nikolaev et al., “TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells,” Nature Immunology, vol. 15, no. 7, pp. 676–686, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Xu, R. M. Williams, D. Holowka, and B. Baird, “Stimulated release of fluorescently labeled IgE fragments that efficiently accumulate in secretory granules after endocytosis in RBL-2H3 mast cells,” Journal of Cell Science, vol. 111, Part 16, pp. 2385–2396, 1998. View at Google Scholar
  36. J. Schmitz, A. Owyang, E. Oldham et al., “IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines,” Immunity, vol. 23, no. 5, pp. 479–490, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. M. D. Smithgall, M. R. Comeau, B. R. Park Yoon, D. Kaufman, R. Armitage, and D. E. Smith, “IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells,” International Immunology, vol. 20, no. 8, pp. 1019–1030, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Suzukawa, M. Iikura, R. Koketsu et al., “An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor,” The Journal of Immunology, vol. 181, no. 9, pp. 5981–5989, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Suzukawa, R. Koketsu, M. Iikura et al., “Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils,” Laboratory Investigation, vol. 88, no. 11, pp. 1245–1253, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. S. H. Mun, N. Y. Ko, H. S. Kim et al., “Interleukin-33 stimulates formation of functional osteoclasts from human CD14+ monocytes,” Cellular and Molecular Life Sciences, vol. 67, no. 22, pp. 3883–3892, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Kurowska-Stolarska, B. Stolarski, P. Kewin et al., “IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation,” The Journal of Immunology, vol. 183, no. 10, pp. 6469–6477, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. A. D. Joshi, S. R. Oak, A. J. Hartigan et al., “Interleukin-33 contributes to both M1 and M2 chemokine marker expression in human macrophages,” BMC Immunology, vol. 11, no. 1, p. 52, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. D. R. Neill, S. H. Wong, A. Bellosi et al., “Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity,” Nature, vol. 464, no. 7293, pp. 1367–1370, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. K. Moro, T. Yamada, M. Tanabe et al., “Innate production of TH2 cytokines by adipose tissue-associated c-Kit+Sca-1+ lymphoid cells,” Nature, vol. 463, pp. 540–544, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. M. A. Rank, T. Kobayashi, H. Kozaki, K. R. Bartemes, D. L. Squillace, and H. Kita, “IL-33-activated dendritic cells induce an atypical TH2-type response,” The Journal of Allergy and Clinical Immunology, vol. 123, no. 5, pp. 1047–1054, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. H. R. Turnquist, T. L. Sumpter, A. Tsung et al., “IL-1β-driven ST2L expression promotes maturation resistance in rapamycin-conditioned dendritic cells,” The Journal of Immunology, vol. 181, no. 1, pp. 62–72, 2008. View at Publisher · View at Google Scholar
  47. J. C. Alves-Filho, F. Sônego, F. O. Souto et al., “Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection,” Nature Medicine, vol. 16, no. 6, pp. 708–712, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Komai-Koma, D. S. Gilchrist, A. N. J. McKenzie, C. S. Goodyear, D. Xu, and F. Y. Liew, “IL-33 activates B1 cells and exacerbates contact sensitivity,” The Journal of Immunology, vol. 186, no. 4, pp. 2584–2591, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. E. Bourgeois, L. P. van, M. Samson et al., “The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production,” European Journal of Immunology, vol. 39, no. 4, pp. 1046–1055, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. Q. Yang, G. Li, Y. Zhu et al., “IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells,” European Journal of Immunology, vol. 41, no. 11, pp. 3351–3360, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. W. V. Bonilla, A. Frohlich, K. Senn et al., “The alarmin interleukin-33 drives protective antiviral CD8+ T cell responses,” Science, vol. 335, no. 6071, pp. 984–989, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. A. M. Miller and F. Y. Liew, “The IL-33/ST2 pathway--a new therapeutic target in cardiovascular disease,” Pharmacology & Therapeutics, vol. 131, no. 2, pp. 179–186, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. A. M. Miller, D. Xu, D. L. Asquith et al., “IL-33 reduces the development of atherosclerosis,” The Journal of Experimental Medicine, vol. 205, no. 2, pp. 339–346, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Hasan, F. al-Ghimlas, S. Warsame et al., “IL-33 is negatively associated with the BMI and confers a protective lipid/metabolic profile in non-diabetic but not diabetic subjects,” BMC Immunology, vol. 15, no. 1, p. 19, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. P. H. Marathe, H. X. Gao, and K. L. Close, “American Diabetes Association standards of medical care in diabetes 2017,” Journal of Diabetes, vol. 9, no. 4, pp. 320–324, 2017. View at Publisher · View at Google Scholar · View at Scopus
  56. American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 37, Supplement 1, pp. S81–S90, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. The International Expert Committee, “International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes,” Diabetes Care, vol. 32, no. 7, pp. 1327–1334, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. R. Ahmad, P. K. Shihab, R. Thomas et al., “Increased expression of the interleukin-1 receptor-associated kinase (IRAK)-1 is associated with adipose tissue inflammatory state in obesity,” Diabetology and Metabolic Syndrome, vol. 7, no. 1, p. 71, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. J. Zhao, J. Wei, R. K. Bowser, R. S. Traister, M. H. Fan, and Y. Zhao, “Focal adhesion kinase-mediated activation of glycogen synthase kinase 3β regulates IL-33 receptor internalization and IL-33 signaling,” The Journal of Immunology, vol. 194, no. 2, pp. 795–802, 2015. View at Publisher · View at Google Scholar · View at Scopus
  60. C. Cayrol and J. P. Girard, “The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 22, pp. 9021–9026, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. A. U. Lüthi, S. P. Cullen, E. A. McNeela et al., “Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases,” Immunity, vol. 31, no. 1, pp. 84–98, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. P. A. Tataranni and E. Ortega, “A burning question: does an adipokine-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes?” Diabetes, vol. 54, no. 4, pp. 917–927, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Zeyda and T. M. Stulnig, “Adipose tissue macrophages,” Immunology Letters, vol. 112, no. 2, pp. 61–67, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. P. J. Murray, J. E. Allen, S. K. Biswas et al., “Macrophage activation and polarization: nomenclature and experimental guidelines,” Immunity, vol. 41, no. 1, pp. 14–20, 2014. View at Publisher · View at Google Scholar · View at Scopus
  65. G. Chinetti-Gbaguidi and B. Staels, “Macrophage polarization in metabolic disorders: functions and regulation,” Current Opinion in Lipidology, vol. 22, no. 5, pp. 365–372, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. J. C. Gensel, T. J. Kopper, B. Zhang, M. B. Orr, and W. M. Bailey, “Predictive screening of M1 and M2 macrophages reveals the immunomodulatory effectiveness of post spinal cord injury azithromycin treatment,” Scientific Reports, vol. 7, no. 1, p. 40144, 2017. View at Publisher · View at Google Scholar · View at Scopus
  67. D. L. Morris, K. Singer, and C. N. Lumeng, “Adipose tissue macrophages: phenotypic plasticity and diversity in lean and obese states,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 14, no. 4, pp. 341–346, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Kato, S. Khan, E. d'Aniello, K. J. McDonald, and D. N. J. Hart, “The novel endocytic and phagocytic C-type lectin receptor DCL-1/CD302 on macrophages is colocalized with F-actin, suggesting a role in cell adhesion and migration,” The Journal of Immunology, vol. 179, no. 9, pp. 6052–6063, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. T. H. Lo, P. A. Silveira, P. D. Fromm et al., “Characterization of the expression and function of the C-type lectin receptor CD302 in mice and humans reveals a role in dendritic cell migration,” The Journal of Immunology, vol. 197, no. 3, pp. 885–898, 2016. View at Publisher · View at Google Scholar · View at Scopus
  70. D. Strodthoff, Z. Ma, T. Wirström et al., “Toll-like receptor 3 influences glucose homeostasis and β-cell insulin secretion,” Diabetes, vol. 64, no. 10, pp. 3425–3438, 2015. View at Publisher · View at Google Scholar · View at Scopus
  71. G. M. Barton, J. C. Kagan, and R. Medzhitov, “Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA,” Nature Immunology, vol. 7, no. 1, pp. 49–56, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. M. L. Mouchess, N. Arpaia, G. Souza et al., “Transmembrane mutations in Toll-like receptor 9 bypass the requirement for ectodomain proteolysis and induce fatal inflammation,” Immunity, vol. 35, no. 5, pp. 721–732, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Feuerer, L. Herrero, D. Cipolletta et al., “Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters,” Nature Medicine, vol. 15, no. 8, pp. 930–939, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Nishimura, I. Manabe, M. Nagasaki et al., “CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity,” Nature Medicine, vol. 15, no. 8, pp. 914–920, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Winer, Y. Chan, G. Paltser et al., “Normalization of obesity-associated insulin resistance through immunotherapy,” Nature Medicine, vol. 15, no. 8, pp. 921–929, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. D. A. A. Vignali and V. K. Kuchroo, “IL-12 family cytokines: immunological playmakers,” Nature Immunology, vol. 13, no. 8, pp. 722–728, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. L. Sun, C. He, L. Nair, J. Yeung, and C. E. Egwuagu, “Interleukin 12 (IL-12) family cytokines: role in immune pathogenesis and treatment of CNS autoimmune disease,” Cytokine, vol. 75, no. 2, pp. 249–255, 2015. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Li, Y. Li, X. Liu, X. Gao, and Y. Wang, “IL-33 blockade suppresses the development of experimental autoimmune encephalomyelitis in C57BL/6 mice,” Journal of Neuroimmunology, vol. 247, no. 1-2, pp. 25–31, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. H. R. Jiang, M. Milovanović, D. Allan et al., “IL-33 attenuates EAE by suppressing IL-17 and IFN-γ production and inducing alternatively activated macrophages,” European Journal of Immunology, vol. 42, no. 7, pp. 1804–1814, 2012. View at Publisher · View at Google Scholar · View at Scopus
  80. B. M. Matta, J. M. Lott, L. R. Mathews et al., “IL-33 is an unconventional alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2+ regulatory T cells,” The Journal of Immunology, vol. 193, no. 8, pp. 4010–4020, 2014. View at Publisher · View at Google Scholar · View at Scopus
  81. C. W. Y. Chan, L. S. Kay, R. G. Khadaroo et al., “Soluble fibrinogen-like protein 2/fibroleukin exhibits immunosuppressive properties: suppressing T cell proliferation and inhibiting maturation of bone marrow-derived dendritic cells,” The Journal of Immunology, vol. 170, no. 8, pp. 4036–4044, 2003. View at Publisher · View at Google Scholar · View at Scopus
  82. I. Shalev, K. M. Wong, K. Foerster et al., “The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis,” Hepatology, vol. 49, no. 2, pp. 387–397, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. K. Foerster, A. Helmy, Y. Zhu et al., “The novel immunoregulatory molecule FGL2: a potential biomarker for severity of chronic hepatitis C virus infection,” Journal of Hepatology, vol. 53, no. 4, pp. 608–615, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. Z. Zhao, C. Yang, L. Wang et al., “The regulatory T cell effector soluble fibrinogen-like protein 2 induces tubular epithelial cell apoptosis in renal transplantation,” Experimental Biology and Medicine, vol. 239, no. 2, pp. 193–201, 2014. View at Publisher · View at Google Scholar · View at Scopus
  85. I. Shalev, H. Liu, C. Koscik et al., “Targeted deletion of fgl2 leads to impaired regulatory T cell activity and development of autoimmune glomerulonephritis,” The Journal of Immunology, vol. 180, no. 1, pp. 249–260, 2007. View at Publisher · View at Google Scholar
  86. J. R. Brestoff, B. S. Kim, S. A. Saenz et al., “Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity,” Nature, vol. 519, no. 7542, pp. 242–246, 2015. View at Publisher · View at Google Scholar · View at Scopus
  87. M. W. Lee, J. I. Odegaard, L. Mukundan et al., “Activated type 2 innate lymphoid cells regulate beige fat biogenesis,” Cell, vol. 160, no. 1-2, pp. 74–87, 2015. View at Publisher · View at Google Scholar · View at Scopus